JPRN-UMIN000019942已完成2 期
ong-term study of KW-0761 in patients with HAM - 0761HAM
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with a history of acute or chronic hepatitis or hepatic cirrhosis (2)Patients with a history of tuberculosis or with active tuberculosis (3)Patients who have developed a myocardial infarction within 12 months of enrollment (4)Patients with a history of allergic reaction to antibody-based treatments (5)Patients who have taken immunosuppressant drugs or interferon-a within 6 months of enrollment (6)Patients who have undergone live or attenuated/inactivated vaccinations within four weeks of enrollment, or who plan to be vaccinated during the course of the study (7)Patients with serious complicating conditions (8)Patients with any ailment that could be exacerbated by the administration of KW-0761 (9)Patients with a history of cancer with complications. However, the following patients are not excluded: - radically resected solid tumor which have not recurred within the five years preceding enrollment - radically resected basal cell carcinoma of the skin, squamous cell carcinoma (except malignant melanoma), non-invasive cervix carcinoma, and carcinoma in situ in the gastrointestinal tract or corpus of the uterus even if recurrence has occurred within five years of enrollment (10)Patients with ATL (11)Patients who are pregnant, breastfeeding, or may become pregnant (12)Patients taking multivitamins (prosultiamine, vitamin C) or supplements such as fucoidan, catechin, or pentosan polysulfate within two weeks of enrollment (13)Patients who have taken other experimental drugs within four months of giving informed consent (14)Patients with spinal cord compression lesion complications such as from cervical spine disease, intervertebral disc herniation, yellow ligament ossification (15)Patients with mental disabilities, epilepsy, or dementia (16)HBsAg-, anti-HBc- or HBV-DNA-positive patients (17)HCV antibody-positive patients (18)HIV antibody-positive patients (19)Patients considered unqualified to join the study by the investigators
研究者
相似试验
未知
3 期
Phase 3 study of KHK7580Secondary hyperparathyroidism receiving peritoneal dialysisJPRN-jRCT2080222964Kyowa Hakko Kirin Co., Ltd.30
未知
1 期
KHK6640 Phase1 study (A repeated dose study in patients with Alzheimer's disease)Alzheimer's disease (AD)JPRN-jRCT2080223486Kyowa Hakko Kirin Co., Ltd.5
未知
3 期
ong term study of VAH631 in patients with essential hypertension (Extension from B1303 study)HypertensionJPRN-jRCT2080220261ovartis Pharma K.K.350
已完成
不适用
Effect of HLJG0701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical TrialKCT0003010Hwajin80
已完成
2 期
Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeMyelokathexisInfectionsNeutropeniaWartsHypogammaglobulinemiaNCT02231879National Institute of Allergy and Infectious Diseases (NIAID)20